Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01364649 · ClinicalTrials.gov registry record · Phase 3
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
A Phase 3 study of Treatment Outcome, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 447
- Enrollment target
- 20
- Study locations
NCT01364649 is a Phase 3 study of Treatment Outcome that has completed, run by Takeda. The registered enrollment target is 447 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT01364649, a Phase 3 study of Treatment Outcome, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 447 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Escitalopram
- DRUG Vortioxetine
Study Locations (20)
California
- - Anaheim
- - Chino
- - Costa Mesa
- - Encino
- - Escondido
- - Irvine
- - Newport Beach
- - Oceanside
- - San Diego
Florida
- - Coral Springs
- - Fort Myers
- - Gainesville
- - Jacksonville
- - Lauderhill
- - North Miami
- - Orlando
Alabama
- - Birmingham
Arizona
- - Tucson
Connecticut
- - Norwich
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01364649
The ClinicalTrials.gov registry entry for NCT01364649 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment Outcome appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01364649 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01364649 about?
NCT01364649 is a clinical study titled "Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction". The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
What is the current status of trial NCT01364649?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 447 participants. The study started on 2011-06. Estimated completion is 2013-12.
What conditions does trial NCT01364649 study?
This clinical trial studies the following conditions: Treatment Outcome.
What interventions are being tested in trial NCT01364649?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT01364649?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01364649 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment Outcome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.